NCT06885606

Brief Summary

Project Summary - tDCS for Vaping Reduction Background: While the prevalence of tobacco smoking has plateaued over the last several years, the prevalence of nicotine vaping (e-cigarettes) continues to increase exponentially in Canada. Originally touted as a safe alternative to smoking, e-cigarette use or vaping is now most popular among youth and young adults. The high prevalence of e-cigarette use, coupled with growing evidence of associated harms and reports of addiction and difficulties in quitting reinforces the urgent need to develop and test methods to attenuate e-cigarette craving as a step towards developing approaches to vaping cessation that are brief, inexpensive and effective. Non-invasive brain stimulation techniques have become a popular area of research as a treatment option for substance use disorders with growing evidence of their effectiveness for a variety of addictions. One of these techniques, transcranial direct current stimulation (tDCS), has been shown to decrease cigarette craving and consumption. Thus, the purpose of this pilot study is to evaluate the effectiveness of using tDCS for vaping reduction in e-cigarette users. Methods: This will be a double-blind sham-controlled randomized trial whereby 40 daily nicotine-containing e-cigarette users will be recruited to undergo 10 consecutive daily sessions of tDCS (Monday to Friday for 2 weeks). Participants will be randomized (1:1) to either sham (0mA) or active tDCS (2mA), with the anode at the left dorsolateral prefrontal cortex (DLPFC) and cathode at the right DLPFC. The primary outcome is vaping frequency (puffs/day and nicotine pods/week) at end of treatment (2 weeks). The secondary outcome will be e-cigarette craving. Participants will be followed-up via the phone at 1 month and 3 months post randomization respectively. Implication: This will be the first treatment study to target vaping reduction. There are currently no established treatment options for e-cigarette addiction and medications traditionally used for smoking cessation only address withdrawal symptoms and not addiction pathology. Thus, findings from this study may be used to inform future designs of vaping reduction strategies or vaping cessation.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 19, 2023

Completed
1.3 years until next milestone

First Posted

Study publicly available on registry

March 20, 2025

Completed
10 months until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

March 19, 2026

Status Verified

March 1, 2026

Enrollment Period

3 months

First QC Date

December 19, 2023

Last Update Submit

March 17, 2026

Conditions

Keywords

E-cigarettesVapingBrain stimulationtDCSNicotine

Outcome Measures

Primary Outcomes (1)

  • Explore the efficacy of tDCS for reducing vaping use.

    The primary outcome is frequency of vape use at end of treatment (2 week period), measured by self-reported vaping frequency (puffs/day) and nicotine pods/week (estimate total nicotine consumed per week).

    2 weeks

Secondary Outcomes (1)

  • Explore changes in craving that are associated with tDCS intervention.

    2 weeks

Study Arms (2)

Active tDCS stimulation group

ACTIVE COMPARATOR
Device: Active tDCS

Sham tDCS stimulation group

SHAM COMPARATOR

Sham tDCS applies a 2mA current for the initial 30 seconds, followed by 0 mA for the remaining 19.5 minutes to simulate active tDCS stimulation. The cathode electrode is placed on the right dorsolateral prefrontal cortex (DLPFC), and the anode is positioned on the left DLPFC, aligned with the electrode placement used in active tDCS.

Device: Sham tDCS

Interventions

Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that involves brief (e.g., 20-min) application of weak electric current (e.g., 2 mA) to the scalp. Active tDCS intervention increases excitability of neurons at the anode with 20-30% of the current going through the brain from anode to cathode so that both cortical and subcortical structures are stimulated. The procedure is very safe, convenient, and fast-acting with well-established parameters. It has the ability to modulate plasticity in specific brain areas and has established efficacy in human laboratory models of addictive motivation and has been shown to decrease craving for cigarettes when the anode is placed over the left dorsolateral prefrontal cortex (DLPFC).

Active tDCS stimulation group
Sham tDCSDEVICE

Sham tDCS applies a 2mA current for the initial 30 seconds, followed by 0 mA for the remaining 19.5 minutes to simulate active tDCS stimulation. The cathode electrode is placed on the right dorsolateral prefrontal cortex (DLPFC), and the anode is positioned on the left DLPFC, aligned with the electrode placement used in active tDCS.

Sham tDCS stimulation group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Be able to provide informed written consent
  • Stated willingness to comply with all study procedures
  • Age 18 - 65 years
  • Is a daily regular use of nicotine-containing e-cigarette for at least the past 6 months
  • Is willing to attend daily appointments for tDCS for two consecutive weeks (Monday through Friday)
  • Is not interested in or planning to quit vaping in the next 30 days.

You may not qualify if:

  • An individual who meets any of the following criteria will be excluded from participation in this research study:
  • Substance use disorder (other than nicotine dependence) (M.I.N.I. SCID) (confirmed with urine drug screen)
  • Current regular use of tobacco cigarettes, nicotine replacement therapy or other medications for smoking cessation
  • Unstable psychiatric condition
  • Recent clinically significant head trauma\*
  • History of seizures and/or epilepsy\*
  • Pacemakers or implanted electrical devices such as cochlear implants\*
  • Metal embedded in the skull\*
  • Skin lesions, open wounds, bruising, or similar injuries on the scalp\*

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre for Addiction and Mental Health

Toronto, Ontario, M6J 1H4, Canada

RECRUITING

MeSH Terms

Conditions

VapingBehavior, Addictive

Condition Hierarchy (Ancestors)

SmokingBehaviorCompulsive BehaviorImpulsive Behavior

Central Study Contacts

Eunice Chen, M.Sc.

CONTACT

Kameron Iturralde, B.Sc.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Scientist

Study Record Dates

First Submitted

December 19, 2023

First Posted

March 20, 2025

Study Start

January 1, 2026

Primary Completion

April 1, 2026

Study Completion

May 1, 2026

Last Updated

March 19, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations